SBILIFE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.9
| Stock Code | SBILIFE | Market Cap | 1,82,449 Cr. | Current Price | 1,819 ₹ | High / Low | 2,133 ₹ |
| Stock P/E | 73.9 | Book Value | 190 ₹ | Dividend Yield | 0.15 % | ROCE | 15.0 % |
| ROE | 13.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,910 ₹ | DMA 200 | 1,898 ₹ |
| Chg in FII Hold | -0.37 % | Chg in DII Hold | 0.41 % | PAT Qtr | 805 Cr. | PAT Prev Qtr | 577 Cr. |
| RSI | 41.5 | MACD | -27.1 | Volume | 11,21,750 | Avg Vol 1Wk | 16,47,437 |
| Low price | 1,663 ₹ | High price | 2,133 ₹ | PEG Ratio | 5.77 | Debt to equity | 0.00 |
| 52w Index | 33.2 % | Qtr Profit Var | -1.09 % | EPS | 24.6 ₹ | Industry PE | 70.0 |
📉 Optimal Buy Price (Today): 1,805–1,815 ₹
🎯 Profit Exit Levels: 1,835–1,845 ₹ (short scalp), 1,860–1,870 ₹ (extended momentum)
🛑 Stop-Loss: 1,790 ₹
⏳ If Already Holding: Exit near 1,835–1,845 ₹ if momentum weakens. Watch RSI recovery above 45 and volume expansion for continuation. Tighten stop-loss if price fails to sustain above 1,810 ₹ intraday.
Positive
✔️ Strong market cap of 1,82,449 Cr.
✔️ EPS at 24.6 ₹ shows earnings consistency
✔️ Debt-free balance sheet (Debt-to-equity: 0.00)
✔️ DII holdings increased (+0.41%)
Limitation
⚠️ RSI at 41.5 indicates weak momentum
⚠️ MACD negative (-27.1) reflects bearish bias
⚠️ Price below 50 DMA (1,910 ₹) and 200 DMA (1,898 ₹) — trend pressure
⚠️ High P/E ratio (73.9) compared to industry average
Company Negative News
📉 FII holdings declined (-0.37%)
📉 Quarterly profit variation negative (-1.09%)
📉 Volume below weekly average (11.2L vs 16.4L)
Company Positive News
📈 PAT growth from 577 Cr. to 805 Cr. (YoY strength despite QoQ dip)
📈 Dividend yield maintained at 0.15%
📈 52-week index performance strong at 33.2%
Industry
🏦 Industry PE at 70.0 vs SBILIFE’s 73.9 — slightly overvalued relative to peers
🏦 Insurance sector showing steady demand but valuation concerns persist
Conclusion
🔎 SBILIFE offers fundamental stability but weak technicals for intraday trading.
Short-term bounce possible from oversold RSI, but momentum remains fragile below DMA levels.
Best suited for cautious intraday scalps with strict stop-loss discipline rather than aggressive trades.
Would you like me to extend this into a sector overlay with peer benchmarking (HDFCLIFE, ICICIPRULI, MAXFIN) so you can compare SBILIFE’s intraday strength against other insurance stocks?